The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Sarcopenia and frailty in decompensated cirrhosis
Open accessAbstract
Summary In patients with decompensated cirrhosis, sarcopenia and frailty are prevalent. Although several definitions exist for these terms, in the field of hepatology, sarcopenia has commonly been defined as loss of muscle mass, and frailty has been broadly defined as the phenotypic manifestation of the loss of muscle function. Prompt recognition and accurate assessment of these conditions are critical as they are both strongly associated with morbidity, mortality, poor quality of life and worse post-liver transplant outcomes in patients with cirrhosis. In this review, we describe the complex pathophysiology that underlies the clinical phenotypes of sarcopenia and frailty, their association with decompensation, and provide an overview of tools to assess these conditions in patients with cirrhosis. When available, we highlight data focusing on patients with acutely decompensated cirrhosis, such as inpatients, as this is an area of unmet clinical need. Finally, we discuss management strategies to reverse and/or prevent the development of sarcopenia and frailty, which include adequate nutritional intake of calories and protein, as well as regular exercise of at least moderate intensity, with a mix of aerobic and resistance training. Key knowledge gaps in our understanding of sarcopenia and frailty in decompensated cirrhosis remain, including best methods to measure muscle mass and function in the inpatient setting, racial/ethnic variation in the development and presentation of sarcopenia and frailty, and optimal clinical metrics to assess response to therapeutic interventions that translate into a reduction in adverse outcomes associated with these conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frailty in Older Adults: Evidence for a Phenotype
Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W. J., Burke, G., et al. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.3.m146 · Cited by 24,907
Mitochondrial TCA cycle metabolites control physiology and disease
Martínez-Reyes, I., & Chandel, N. S. (2020) · Nature Communications · doi:10.1038/s41467-019-13668-3 · Cited by 2,813
Taylor, B. E., McClave, S. A., Martindale, R. G., Warren, M. M., Johnson, D. R., Braunschweig, C., McCarthy, M. S., Davanos, E., Rice, T. W., Cresci, G. A., et al. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001525 · Cited by 1,476
Neural mechanisms of ageing and cognitive decline
Bishop, N. A., Lu, T., & Yankner, B. A. (2010) · Nature · doi:10.1038/nature08983 · Cited by 1,323
EASL Clinical Practice Guidelines on nutrition in chronic liver disease
Merli, M., Berzigotti, A., Zelber-Sagi, S., Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., & Parés, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.024 · Cited by 1,130
Self-citationSkeletal muscle hypertrophy and atrophy signaling pathways
Glass, D. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.04.018 · Cited by 1,106
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Interleukin‐6 myokine signaling in skeletal muscle: a double‐edged sword?
Muñoz‐Cánoves, P., Scheele, C., Pedersen, B. K., & Serrano, A. L. (2013) · The FEBS Journal · doi:10.1111/febs.12338 · Cited by 774
ESPEN guideline on clinical nutrition in liver disease
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674
Self-citationSarcopenia from mechanism to diagnosis and treatment in liver disease
Dasarathy, S., & Merli, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.040 · Cited by 608
Self-citation
Cited by
Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis
Tantai, X., Liu, Y., Yeo, Y. H., Praktiknjo, M., Mauro, E., Hamaguchi, Y., Engelmann, C., Zhang, P., Jeong, J. Y., van Vugt, J. L. A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.006 · Cited by 426
EASL Clinical Practice Guidelines on acute-on-chronic liver failure
Moreau, R., Tonon, M., Krag, A., Angeli, P., Berenguer, M., Berzigotti, A., Fernandez, J., Francoz, C., Gustot, T., Jalan, R., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.021 · Cited by 375
Meena, B. L., Taneja, S., Tandon, P., Sahni, N., Soundararajan, R., Gorsi, U., De, A., Verma, N., Premkumar, M., Duseja, A., et al. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16035 · Cited by 36
Self-citationEmerging Roles of High-mobility Group Box-1 in Liver Disease
Wang, L., Dong, Z., Zhang, Y., & Peng, L. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00317 · Cited by 8
Metadata
- Authors
- Tandon, P., Montano-Loza, A. J., Lai, J. C., Dasarathy, S., & Merli, M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 75
- Pages
- S147-S162
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3164554479
- Cited by
- 408
- References
- 128
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcopenia and frailty in decompensated cirrhosis. https://app.cochat.ai/papers/10.1016/j.jhep.2021.01.025
- The paper
- Tandon, P., Montano-Loza, A. J., Lai, J. C., Dasarathy, S., & Merli, M. (2021). Sarcopenia and frailty in decompensated cirrhosis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.01.025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.